In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 1745-07-9, name is 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline, introducing its new discovery. Recommanded Product: 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline
Conformationally-flexible benzamide analogues as dopamine D3 and sigma2 receptor ligands
A series of conformationally-flexible analogues was prepared and their affinities for D2-like dopamine (D2, D3 and D 4) were determined using in vitro radioligand binding assays. The results of this structure-activity relationship study identified one compound, 15, that bound with high affinity (Ki value=2 nM) and moderate selectivity (30-fold) for D3 compared to D2 receptors. In addition, this series of compounds were also tested for affinity at sigma 1 and sigma2 receptors. We evaluated the affinity of these dopaminergic compounds at sigma receptors because (a) several antipsychotic drugs, which are high affinity antagonists at dopamine D 2-like receptors, also bind to sigma receptors and (b) sigma receptors are expressed ubiquitously and at high levels (picomoles per mg proteins). It was observed that a number of analogues displayed high affinity and excellent selectivity for sigma2 versus sigma1 receptors. Consequently, these novel compounds may be useful for characterizing the functional role of sigma2 receptors and for imaging the sigma2 receptor status of tumors in vivo with PET.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 1745-07-9, and how the biochemistry of the body works.Recommanded Product: 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline
Reference£º
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem